Medicenna Therapeutics Corp. (MDNA) Social Stream
MEDICENNA THERAPEUTICS CORP (MDNA) Price Targets From Analysts
Use the tables below to see what analysts covering MEDICENNA THERAPEUTICS CORP think about its future price and what recommendations they have for investors and traders.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-11-16 | 4 | $12 | $7 | $10.018 | $0.181 | 5434.81% |
2022-02-10 | 5 | $12 | $7 | $9.685 | $0.181 | 5250.83% |
2022-04-12 | 5 | $12 | $7 | $9.671 | $0.181 | 5243.09% |
2022-06-03 | 5 | $12 | $4 | $9.171 | $0.181 | 4966.85% |
2022-07-28 | 5 | $11 | $4 | $7.985 | $0.181 | 4311.6% |
2022-08-15 | 5 | $11 | $4 | $7.651 | $0.181 | 4127.07% |
2022-09-29 | 5 | $10.14 | $4 | $7.151 | $0.181 | 3850.83% |
2022-11-06 | 4 | $9 | $4 | $6.4 | $0.181 | 3435.91% |
2022-11-16 | 3 | $9 | $2.5 | $6.1 | $0.181 | 3270.17% |
2023-04-19 | 4 | $9 | $2.5 | $6.1 | $0.181 | 3270.17% |
2023-07-31 | 4 | $9 | $2.5 | $6.625 | $0.181 | 3560.22% |
2023-08-10 | 4 | $8 | $2.5 | $5.875 | $0.181 | 3145.86% |
2023-08-15 | 3 | $7 | $2.5 | $5.166 | $0.181 | 2754.14% |
The Trend in the Analyst Price Target
MDNA's average price target has moved down $1.98 over the prior 51 weeks.
Over the past 40 weeks, MDNA's average upside potential has been 1,051.07%.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2022-11-08 | 4 | 9 | 2.5 | 6.100 | 0.643 | 848.68% |
2023-03-30 | 4 | 9 | 2.5 | 6.100 | 0.610 | 900% |
2023-04-19 | 4 | 9 | 2.5 | 6.625 | 0.619 | 970.27% |
2023-08-10 | 4 | 8 | 2.5 | 5.875 | 0.400 | 1368.75% |
2023-08-15 | 3 | 7 | 2.5 | 4.625 | 0.409 | 1030.81% |
MDNA Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
Over the past 26 weeks, MDNA's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, MEDICENNA THERAPEUTICS CORP's upside potential (average analyst target price relative to current price) is greater than 1588.89% of them.
- MDNA has a greater average analyst price target than 115.08% of all US stocks.
- MEDICENNA THERAPEUTICS CORP's number of analysts covering the stock is higher than 1289.61% of stocks in the micro market cap category.
- MEDICENNA THERAPEUTICS CORP's variance in analysts' estimates is lower than -1177.26% of stocks in the micro market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to MEDICENNA THERAPEUTICS CORP are REVB, VIRI, and BPTS.
View All Top Stocks by Price Target
Is MDNA a Buy, Hold or Sell? See the POWR Ratings now!